BAALC Human

Brain and Acute Leukemia Cytoplasmatic Human Recombinant
Cat. No.
BT26292
Source
Escherichia Coli.
Synonyms
Brain and acute leukemia cytoplasmic protein, FLJ12015, BAALC.
Appearance
Sterile filtered colorless solution.
Purity
Greater than 95.0% as determined by SDS-PAGE.
Usage
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs
In Stock

Description

BAALC Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 165 amino acids (1-145 a.a.) and having a molecular mass of 17.7 kDa. The BAALC protein is fused to a 20 amino acid His Tag at N-terminus and purified by standard chromatogrpahy techniques.

Product Specs

Introduction
The BAALC gene is present in patients diagnosed with acute myeloid leukemia. It is conserved in mammals but absent in less complex organisms. BAALC expression is observed in tissues derived from the neuroectoderm. This gene is found in both the cell membrane and cytoplasm and exists in multiple alternatively spliced isoforms. Expressed in hematopoietic and neural cells, BAALC interacts with CaMKII? and participates in synaptic function at postsynaptic lipid rafts. Overexpression of BAALC is linked to a negative clinical prognosis and represents a significant risk factor in cytogenetically normal acute myeloid leukemia (AML).
Description
Recombinant human BAALC protein, produced in E. coli, is a single, non-glycosylated polypeptide chain consisting of 165 amino acids (residues 1-145) with a molecular weight of 17.7 kDa. A 20 amino acid His-tag is fused to the N-terminus of the protein. Purification is achieved using standard chromatographic methods.
Physical Appearance
The product is a sterile, colorless solution after filtration.
Formulation
The protein is supplied in a solution containing 20mM Tris buffer (pH 8), 1mM DTT, 20% glycerol, and 2mM EDTA.
Stability
For short-term storage (2-4 weeks), the product should be kept at 4°C. For extended storage, freezing at -20°C is recommended. The addition of a carrier protein (0.1% HSA or BSA) is advisable for long-term storage. Repeated freeze-thaw cycles should be avoided.
Purity
Purity exceeds 95.0% as determined by SDS-PAGE analysis.
Synonyms
Brain and acute leukemia cytoplasmic protein, FLJ12015, BAALC.
Source
Escherichia Coli.
Amino Acid Sequence
MGSSHHHHHH SSGLVPRGSH MGCGGSRADA IEPRYYESWT RETESTWLTY TDSDAPPSAA APDSGPEAGG LHSGMLEDGL PSNGVPRSTA PGGIPNPEKK TNCETQCPNP QSLSSGPLTQ KQNGLQTTEA KRDAKRMPAK EVTINVTDSI QQMDRSRRIT KNCVN.

Product Science Overview

Structure and Expression

BAALC is a non-glycosylated polypeptide chain consisting of 165 amino acids, with a molecular mass of approximately 17.7 kDa . The recombinant form of BAALC is typically produced in Escherichia coli (E. coli) and includes a 20 amino acid His Tag at the N-terminus to facilitate purification . The protein is purified using standard chromatography techniques and is available in a sterile, filtered, colorless solution containing 20mM Tris buffer (pH 8), 1mM DTT, 20% glycerol, and 2mM EDTA .

Functional Role

BAALC is overexpressed in several types of cancer, including acute myeloid leukemia (AML) and breast cancer . In AML, BAALC expression is associated with poor prognosis and increased cell proliferation . In breast cancer, BAALC expression is progressively increased in primary tumors and metastases compared to normal breast tissue . Overexpression of BAALC in breast cancer cells has been shown to enhance proliferation, anchorage-independent growth, invasion, and migration . Conversely, knockdown of BAALC expression reduces these malignant properties .

Mechanism of Action

The oncogenic effects of BAALC are mediated through various signaling pathways. In breast cancer, BAALC-associated migration and invasion are driven by focal adhesion kinase (FAK)-dependent signaling . This process is accompanied by an increase in matrix metalloproteinase (MMP)-9 activity, which plays a role in the degradation of the extracellular matrix, facilitating cancer cell invasion .

Clinical Implications

Given its role in cancer progression, BAALC is a potential therapeutic target. Inhibiting BAALC expression or function could reduce the proliferation and invasiveness of cancer cells, offering a novel approach to cancer treatment. Additionally, BAALC expression levels could serve as a biomarker for prognosis and treatment response in cancers where it is overexpressed .

Storage and Stability

The recombinant BAALC protein should be stored at -20°C for long-term storage, with the addition of a carrier protein such as 0.1% HSA or BSA to prevent degradation . It is important to avoid multiple freeze-thaw cycles to maintain protein integrity .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2024 Thebiotek. All Rights Reserved.